Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an announcement.
Sichuan Kelun-Biotech Biopharmaceutical has subscribed to structured deposit wealth management products totaling RMB390 million with China Zheshang Bank and RMB300 million with Bank of China. These products are principal-guaranteed with floating returns, indicating the company is seeking to enhance returns on idle funds while preserving capital.
The combined RMB690 million in structured deposits crosses the disclosure threshold under Hong Kong listing rules, classifying each bank subscription as a discloseable transaction subject to reporting and announcement requirements. The move underscores the firm’s active treasury management and may modestly improve interest income without diverting resources from its core biopharmaceutical operations.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$526.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a Hong Kong-listed biopharmaceutical company focused on developing and commercializing innovative drugs in China. The company operates in the healthcare and life sciences sector, deploying surplus cash into low-risk financial instruments while pursuing its core pharmaceutical research and commercial activities.
Average Trading Volume: 526,321
Technical Sentiment Signal: Buy
Current Market Cap: HK$113.6B
Learn more about 6990 stock on TipRanks’ Stock Analysis page.